Robyn Karnauskas
Stock Analyst at Truist Securities
(1.92)
# 2,934
Out of 4,829 analysts
182
Total ratings
41.67%
Success rate
-1.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Hold | $333 → $298 | $265.86 | +12.09% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $46.45 | +39.94% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $75.97 | +44.79% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $96.91 | -14.35% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $184.60 | +13.76% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.63 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $118.17 | +187.72% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $1.89 | +1,275.66% | 2 | May 15, 2024 | |
| CHRS Coherus BioSciences | Maintains: Buy | $8 → $7 | $0.97 | +622.62% | 13 | May 13, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,135 | $527.78 | +115.05% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.44 | +594.44% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $2.75 | +227.27% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $74 | $15.10 | +390.07% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $10.64 | +116.17% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $14.02 | +242.37% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $8.28 | +503.86% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $850 | $734.57 | +15.71% | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $424.99 | +19.53% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $22.28 | +61.58% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $44.23 | -43.48% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.53 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $58.86 | +137.85% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $150 | $0.04 | +357,042.86% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.04 | +573.08% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $12.79 | +330.02% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.05 | - | 4 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $2.03 | +1,328.57% | 1 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $13.23 | +2,318.75% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $3.77 | +297.88% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.41 | +633.14% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $0.40 | +21,165.95% | 1 | Oct 8, 2020 |
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $265.86
Upside: +12.09%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $46.45
Upside: +39.94%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $75.97
Upside: +44.79%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $96.91
Upside: -14.35%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $184.60
Upside: +13.76%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.63
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $118.17
Upside: +187.72%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $1.89
Upside: +1,275.66%
Coherus BioSciences
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $0.97
Upside: +622.62%
Regeneron Pharmaceuticals
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $527.78
Upside: +115.05%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.44
Upside: +594.44%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $2.75
Upside: +227.27%
Mar 25, 2024
Reiterates: Buy
Price Target: $74
Current: $15.10
Upside: +390.07%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $10.64
Upside: +116.17%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $14.02
Upside: +242.37%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $8.28
Upside: +503.86%
Mar 22, 2024
Reiterates: Buy
Price Target: $850
Current: $734.57
Upside: +15.71%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $424.99
Upside: +19.53%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $22.28
Upside: +61.58%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $44.23
Upside: -43.48%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.53
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $58.86
Upside: +137.85%
Sep 6, 2023
Reiterates: Buy
Price Target: $150
Current: $0.04
Upside: +357,042.86%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.04
Upside: +573.08%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $12.79
Upside: +330.02%
Dec 6, 2022
Downgrades: Hold
Price Target: n/a
Current: $2.05
Upside: -
Nov 16, 2022
Initiates: Buy
Price Target: $29
Current: $2.03
Upside: +1,328.57%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $13.23
Upside: +2,318.75%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $3.77
Upside: +297.88%
Nov 11, 2020
Initiates: Buy
Price Target: $25
Current: $3.41
Upside: +633.14%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $0.40
Upside: +21,165.95%